FDA-cleared profile

BraveCX

Bering Ltd · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs

Clinical role
Passive notification and prioritization in parallel with standard of care; it does not send a proactive alert, direct attention to image regions, alter the queue, or replace clinical review
Images and patients
X-ray/Radiography · Chest/lung, targeting pleural effusion and pneumothorax
Key limitation
Keep in mind: Not for standalone clinical decision-making; not a proactive alert; not intended to direct attention to specific image portions or findings other than pleural effusion/pneumothorax; technologist notification is contextual and not for clinical prioritization or action

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/lung, targeting pleural effusion and pneumothorax Input: Adult (>=18 years) AP and PA chest X-ray images in DICOM format, received as attached DICOM images or DICOM UIDs referencing stored images
  • Who uses it?Intended users: Appropriately trained medical specialists qualified to interpret chest radiographs, such as radiologists or other appropriately trained clinicians
  • What does the software produce?Output: Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation
  • What is its most important limitation?Key limitation: Not for standalone clinical decision-making; not a proactive alert; not intended to direct attention to specific image portions or findings other than pleural effusion/pneumothorax; technologist notification is contextual and not for clinical prioritization or action

Clinical takeaway. Clinical role: Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs

Evidence takeaway. Evidence from the reviewed source record: Internal independent testing used 1,209 pleural-effusion cases and 1,387 pneumothorax cases from 14 acute NHS sites, with three board-certified radiologist ground truths: sensitivity/specificity 82%/95% for pleural effusion and 89%/97% for pneumothorax. External validation used MIMIC-CXR, NIH-CXR, and CheXpert cohorts: pleural effusion n=2,509 with 867 positives, ROC AUC 0.988, sensitivity 92.62%, specificity 98.11%; pneumothorax n=3,245 with 2,114 positives, ROC AUC 0.972, sensitivity 93.38%, specificity 97.27%. Simultaneous prediction time was 4.8-10.4 seconds (95% CI 4.2-10.41 seconds)

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Passive worklist triage for suspected pleural effusion and/or pneumothorax in adult chest radiographs
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Passive notification and prioritization in parallel with standard of care; it does not send a proactive alert, direct attention to image regions, alter the queue, or replace clinical review
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Adult (>=18 years) AP and PA chest X-ray images in DICOM format, received as attached DICOM images or DICOM UIDs referencing stored images
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Adult standard-of-care chest-radiograph worklist; the indication does not restrict the product to a named institutional setting
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Appropriately trained medical specialists qualified to interpret chest radiographs, such as radiologists or other appropriately trained clinicians
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not for standalone clinical decision-making; not a proactive alert; not intended to direct attention to specific image portions or findings other than pleural effusion/pneumothorax; technologist notification is contextual and not for clinical prioritization or action
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
Internal independent testing used 1,209 pleural-effusion cases and 1,387 pneumothorax cases from 14 acute NHS sites, with three board-certified radiologist ground truths: sensitivity/specificity 82%/95% for pleural effusion and 89%/97% for pneumothorax. External validation used MIMIC-CXR, NIH-CXR, and CheXpert cohorts: pleural effusion n=2,509 with 867 positives, ROC AUC 0.988, sensitivity 92.62%, specificity 98.11%; pneumothorax n=3,245 with 2,114 positives, ROC AUC 0.972, sensitivity 93.38%, specificity 97.27%. Simultaneous prediction time was 4.8-10.4 seconds (95% CI 4.2-10.41 seconds)
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Internal independent testing used 1,209 pleural-effusion cases and 1,387 pneumothorax cases from 14 acute NHS sites, with three board-certified radiologist ground truths: sensitivity/specificity 82%/95% for pleural effusion and 89%/97% for pneumothorax. External validation used MIMIC-CXR, NIH-CXR, and CheXpert cohorts: pleural effusion n=2,509 with 867 positives, ROC AUC 0.988, sensitivity 92.62%, specificity 98.11%; pneumothorax n=3,245 with 2,114 positives, ROC AUC 0.972, sensitivity 93.38%, specificity 97.27%. Simultaneous prediction time was 4.8-10.4 seconds (95% CI 4.2-10.41 seconds)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Pleural Effusion: 92.62%, Pneumothorax: 93.38%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
Pleural Effusion: 98.11%. Pneumothorax: 97.27%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

BraveCX regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K223754
  • Samplen=2981
  • IndependenceIndependence not established

K223754

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K223754. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult (>=18 years) AP and PA chest X-ray images in DICOM format, received as attached DICOM images or DICOM UIDs referencing stored images

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K223754: BraveCX

  2. Routing

    Source context, not route validation: Licensed API described as deployable cloud-based, on premises, or integrated with third-party systems; supports DICOM storage including PACS or other local storage, produces DICOM/JSON results, and displays worklist flags

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K223754: BraveCX

  3. AI processing

    Source context, not route validation: The exact FDA package describes BraveCX as a licensed Application Programming Interface that can be deployed as a cloud-based service, directly on premises, or integrated with third-party systems. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "BraveCX is supplied as a licensed Application Programming Interface (API) that can be deployed either as a cloud-based service, directly on premises, or integrated with third-party systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K223754: BraveCX

  4. Returned objects

    Source context, not route validation: Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K223754: BraveCX

  5. Viewer/worklist/report

    Unresolved route: Case-level flag or blank label for suspected pleural effusion and/or pneumothorax, shown in the PACS/workstation worklist; a newly generated DICOM or JSON result may be stored, with no markup on the original image. The packet also describes a contextual technologist notification within 15 minutes after interpretation

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K223754: BraveCX

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes BraveCX as a licensed Application Programming Interface that can be deployed as a cloud-based service, directly on premises, or integrated with third-party systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "BraveCX is supplied as a licensed Application Programming Interface (API) that can be deployed either as a cloud-based service, directly on premises, or integrated with third-party systems.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Licensed API described as deployable cloud-based, on premises, or integrated with third-party systems; supports DICOM storage including PACS or other local storage, produces DICOM/JSON results, and displays worklist flags
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for BraveCX; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223754
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest/lung, targeting pleural effusion and pneumothorax
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-11-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K223754 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K223754: BraveCX

    U.S. Food and Drug Administration - Published 2023-11-09 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BraveCX model card (K223754)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K223754

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K223754 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243808

Rayvolve PTX-PE

AZmed

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-21
FDA-cleared K232410

SmartChest

Milvue

Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.

Modality
X-ray/Radiography
Anatomy
Chest/lung
Decision
2024-05-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history